撰文丨王聪编辑丨王多鱼排版丨水成文在相当一部分患者中，基于 T 细胞的癌症免疫疗法（例如 CAR-T 细胞疗法、TCR-T 细胞疗法）的持久性仍然有限。肿瘤微环境（TME）中 T 细胞功能障碍是疗效的主要障碍，其部分原因在于 T 细胞耗竭、线粒体功能障碍以及各种免疫抑制因子。尽管在转录组学和表观基因组学方面已对 T ...

T细胞是适应性免疫的中枢介质，通过其抗原特异性T细胞受体（TCRs）识别不同的靶标来协调免疫反应。值得注意的是，基于T细胞的过继免疫疗法在治疗多种癌症、感染和自身免疫性疾病方面取得了显著的成功。然而，有限的扩增潜力和抗原特异性T细胞的耗竭仍然是广泛临床应用的主要障碍。 2026年1月16日，北京大学邓宏魁团队在Cell Research 在线发表题为“Efficient chemical repr ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

该篇日报由R·base创作生成，人工审核校对。Nature：肠菌通过抗原模拟"训练"T细胞，远程支援癌症免疫治疗Nature——[48.5] 背景与设计：为检验肠菌能否通过抗原模拟引发的交叉反应增强癌症免疫治疗，构建表达分节丝状菌（SFB）抗原的小鼠肿瘤模型，结合TCR测序及命运图谱等技术追踪T细胞动态。

T cell development is a tightly regulated process that transforms immature thymocytes into mature T cells with distinct functionalities. In the thymus, precursor cells undergo a series of selection ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

When killer T cells of our immune system divide, they normally undergo asymmetric cell division (ACD): Each daughter cell inherits different cellular components, which drive the cells toward divergent ...

Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...